NHU(SZ:002001) Huachuang Securities·2025-10-31 08:38Investment Rating - The report maintains a "Strong Buy" rating for the company with a target price of 35.1 yuan [2][8]. Core Insights - The company reported a revenue of 16.642 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 5.45%, and a net profit attributable to shareholders of 5.321 billion yuan, up 33.37% year-on-year [2]. - In Q3 2025, the company achieved a revenue of 5.541 billion yuan, with a quarter-on-quarter decrease of 6.66% and a year-on-year decrease of 2.11%. The net profit for Q3 was 1.717 billion yuan, showing a quarter-on-quarter decrease of 3.80% and a year-on-year decrease of 0.35% [2]. - The company is one of the four major vitamin producers globally, with ongoing growth expected from its liquid egg project and other initiatives [8]. Financial Performance Summary - Total revenue projections for 2024A, 2025E, 2026E, and 2027E are 21.610 billion, 26.192 billion, 29.054 billion, and 30.629 billion yuan respectively, with growth rates of 43.0%, 21.2%, 10.9%, and 5.4% [4]. - Net profit attributable to shareholders is projected to be 5.869 billion, 6.530 billion, 7.181 billion, and 7.769 billion yuan for the same years, with growth rates of 117.0%, 11.3%, 10.0%, and 8.2% [4]. - Earnings per share (EPS) are expected to be 1.91, 2.12, 2.34, and 2.53 yuan for 2024A, 2025E, 2026E, and 2027E respectively [4]. Business Development Insights - The company’s vitamin E export volume in Q3 2025 was 31,400 tons, reflecting a quarter-on-quarter increase of 32.63%, indicating resilience during the traditional off-season [8]. - The liquid methionine project, a joint venture with Zhenhai Refining, has begun trial production, with expectations for increased output contributing to the company's performance in H2 2025 [8]. - The company is focusing on expanding its production capacity in methionine, flavor and fragrance, and new materials, with plans to enhance overseas market penetration and product innovation [8].